Alector (STU:0Z2) Treasury Stock : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Alector Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Alector's treasury stock for the quarter that ended in Mar. 2024 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Alector Treasury Stock Historical Data

The historical data trend for Alector's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alector Treasury Stock Chart

Alector Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Get a 7-Day Free Trial

Alector Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Alector Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Alector (STU:0Z2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alector Inc (STU:0Z2) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

ALEC:USA

Address

131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080

Website

https://www.alector.com

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Alector (STU:0Z2) Headlines

No Headlines